In Vivo <i>HOXB7</i> Gene Silencing and Cotreatment with Tamoxifen for Luminal A Breast Cancer Therapy
Background: Acquired resistance and adverse effects are some of the challenges faced by thousands of Luminal A breast cancer patients under tamoxifen (TMX) treatment. Some authors associate the overexpression of HOXB7 with TMX resistance in this molecular subtype, and the knockdown of this gene coul...
Saved in:
Main Authors: | Ana Beatriz Caribé dos Santos Valle (Author), Fábio Fernando Alves da Silva (Author), Maria Ângela Pepe Carneiro (Author), Bruno Espuche (Author), Guilherme Diniz Tavares (Author), Emerson Soares Bernardes (Author), Sergio Enrique Moya (Author), Frederico Pittella (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Therapeutic utility of glucocorticoids and antihistamines cotreatment. Rationale and perspectives
by: Carlos D. Zappia, et al.
Published: (2019) -
HOXB5 expression in oral squamous cell carcinoma
by: Renata Tucci, et al.
Published: (2011) -
The Luminous Face
by: Wells, Carolyn, 1862-1942 -
The Luminous Blonde
by: Howard, Hayden, 1925-2014; Freas, Kelly, 1922-2005 [Illustrator] -
Effect of growth hormone cotreatment in subfertile women ≥ 40 years: a meta-analysis
by: Mohamed Elkalyoubi, et al.
Published: (2023)